To validate the in silico approach, we selected several predicted targets (Camk1d, Glis3, and Jazf1), and one previously validated target (Slc16a1[48]), of miR-29 from among the T2D gene list for evaluation in MIN6 cells. This evidence concerns the gene SLC16A1 and type 2 diabetes mellitus.